Developer docs
API playgroundTry for free, no card

Search company profiles

Cenexi

Full company profile

uuid0009h1u

Namestring
Cenexi
Legal namestring
Cenexi S.A.S.
Websiteurl
cenexi.com
Company typeenum
Private
Founded yearint
2004
Descriptiontext

Cenexi is a French-headquartered Contract Development and Manufacturing Organization (CDMO) founded in 2004 that specializes in sterile injectable pharmaceutical manufacturing. The company operates four production sites — Fontenay-sous-Bois (headquarters), Osny, and H\u00e9rouville-Saint-Clair in France, plus Braine-l'Alleud in Belgium — with a combined workforce of approximately 1,500 people and ~€200M in revenue as of 2021. Cenexi's core capabilities include aseptic filling of ampoules (410 million units/year, the highest capacity in Europe), sterile liquid and freeze-dried vials (68 million/year), pre-filled syringes (37 million/year), and non-sterile forms (tablets, capsules, syrups, creams). The company maintains specialized expertise in high-potency compounds, oncology products, hormonal therapies, narcotics, and biologicals (monoclonal antibodies, ADCs, mRNA/DNA, peptides), supported by six freeze-dryers and dedicated cytotoxic handling infrastructure across multiple sites. Cenexi Services, with 110 dedicated experts, provides formulation, analytical development, industrial transfer, and regulatory support, enabling an end-to-end offering from early development through commercial manufacturing.

Cenexi operates as a B2B contract manufacturer, generating revenue through long-term manufacturing agreements and project-based development services. Its customer base spans large pharmaceutical companies (Sanofi, Piramal), specialty pharma (Advanz, Biocodex, Cheplapharm, Debiopharm, Nordic Pharma, Provepharm, Urogen), generics manufacturers (Arrow, Mithra), and innovative biotechs (Crossject, OSE Immunotherapeutics, Humanigen). The company is registered with health authorities in 124 countries and holds FDA, ANSM, AFMPS, ANVISA, KFDA, and PMDA approvals, enabling global market access for customers. A filed patent for a novel industrial filling process for the Crossject ZENEO® needle-free auto-injector illustrates Cenexi's capability in drug-device combination manufacturing. Cenexi is a wholly-owned subsidiary of Gland Pharma, an Indian pharmaceutical company; Gland Pharma's CDMO segment (anchored by Cenexi) grew 28% in FY26, and Cenexi is expected to deliver low double-digit growth in FY27 with stronger momentum in FY28 as a €100M+ modernization program and new capacity come online. The strategic mix is shifting toward sterile (targeting 80% of revenue by 2026/2027, up from 70% in 2022), with growth driven by biologics manufacturing authorization, new product lines, and long-term commercial supply agreements.

Short descriptiontext

Cenexi is a French CDMO founded in 2004 that manufactures sterile injectable pharmaceuticals — ampoules, vials, pre-filled syringes, and lyophilized products — across four sites in France and Belgium, with specialization in high-potency, oncology, and biological products for ~100 pharmaceutical customers in 124 countries.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
501–1,000
akta.pro rankint
HeadquartersFontenay-sous-bois, France
HQ citystring
Fontenay-sous-bois
HQ countrystring
France
HQ regionstring
Europe
Markets served

Serves global market

Offices4 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
sterile pharmaceutical manufacturing, contract pharmaceutical development, sterile injectable fill-finish, lyophilized drug manufacturing, pharmaceutical CDMO services
Industry4 codes
PRIMARYHLAGABAH
Sterile Fill-Finish & Aseptic Manufacturing CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAC
Biologics (mAbs/Recombinant Proteins) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAG
Drug Substance–Drug Product Integrated CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAK
Clinical Trial Material (CTM) Manufacturing & Supply CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
NAICS code2 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Biological Products, (No Disgnostic Substances)2836
Product category
Pharmaceutical Contract Manufacturing (CDMO)
Social media profiles3 records
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1CDMO Manufacturing Contracts
TypeOthers
Description

Cenexi operates as a Contract Development and Manufacturing Organization (CDMO), generating revenue through long-term manufacturing contracts with pharmaceutical companies, biotechs, and generic manufacturers. Revenue is generated through contractual manufacturing agreements for sterile and non-sterile pharmaceutical forms, with recurring revenue from commercial batches and development fees from new product transfers.

cenexi.com
2Pharmaceutical Development Services
TypeProfessional Services
Description

Cenexi generates revenue from formulation activities, analytical and pharmaceutical form developments, industrial transfer, and regulatory support services through its Cenexi Services entity (110 experts). Services are provided upstream (during drug development) and downstream (regulatory and logistical support), billed as project-based or milestone-based professional services.

cenexi.com
3Parent Company (Gland Pharma) CDMO Integration
TypeOthers
Description

Cenexi, as a European subsidiary of Gland Pharma, contributes to the parent's CDMO business which accounts for nearly half of Gland Pharma's consolidated revenue and grew 28% in FY26. Cenexi is expected to deliver low double-digit revenue growth in FY27 and stronger momentum in FY28 on the back of capacity additions and new product lines.

economictimes.indiatimes.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Operations, Infrastructure, Technology or R&D, Supply Chain, Marketing or Sales
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Cenexi is a French Contract Development and Manufacturing Organization (CDMO) that produces sterile and non-sterile pharmaceutical forms on behalf of pharmaceutical laboratories, innovative biotechs, and generic manufacturers. Its core manufacturing covers injectable ampoules (highest capacity in Europe at 410 million units/year), sterile liquid and freeze-dried vials, and pre-filled syringes, supported by specialized handling of highly potent compounds, cytotoxics, hormones, narcotics, and biological products (mAbs, ADCs, mRNA/DNA, peptides). It complements manufacturing with pharmaceutical development, industrial transfer, regulatory support, and stability testing services.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 8 values shown
  • 410 million ampoules produced annually — highest capacity in Europe
+7 more records
Product overview1 text field

Cenexi is a French Contract Development and Manufacturing Organization (CDMO) founded in 2004, operating as a single integrated offering with four production sites (Fontenay-sous-Bois, Osny, and Hérouville-Saint-Clair in France; Braine-l'Alleud in Belgium). The company provides an end-to-end service spanning pharmaceutical development (via Cenexi Services with 110 experts), regulatory support, manufacturing, and packaging. The core products include sterile forms (ampoules, vials, pre-filled syringes) representing approximately 70% of business, and non-sterile forms (tablets, capsules, syrups, creams, lotions, drops). Special capabilities cover narcotics/psychotropics, highly potent compounds (allergens, hormones, oncology), and biological products (monoclonal antibodies, ADC, mRNA/DNA, peptides). The company serves innovative biotechs as a preferred partner while also manufacturing commercial batches for generic and originator pharma companies, with registrations in 124 countries worldwide.

Product and service16 records
1Injectable Ampoules
CategorySterile injectable manufacturing
Description

Aseptic filling of injectable ampoules (1-25 ml) with the highest production capacity in Europe at 410 million units per year across 8 filling lines (6 at Fontenay-sous-Bois, 2 at Hérouville-Saint-Clair); three lines are Annex 1-compliant.

2Sterile Vials (Liquid and Freeze-dried)
CategorySterile injectable manufacturing
Description

Sterile liquid and freeze-dried vials (2-100 ml) with combined capacity of 68 million units per year across two filling lines at Braine-l'Alleud and Hérouville-Saint-Clair; six freeze dryers with 110 m² useful area, Annex 1-compliant.

3Pre-filled Syringes
CategorySterile injectable manufacturing
Description

Sterile pre-filled syringes (1-50 ml) manufactured at Hérouville-Saint-Clair and Braine-l'Alleud with combined capacity of 37 million units per year, supporting conventional, highly potent, and biological substances including mRNA, DNA, peptides/proteins, monoclonal antibodies, and ADC.

4Tablets
CategoryNon-sterile pharmaceutical manufacturing
Description

Non-sterile tablet manufacturing with capacity of 1 billion tablets per year including hormonal tablets; capabilities in direct compression, wet/alcohol granulation, double compression, and coating at Fontenay-sous-Bois and Osny sites; handles conventional and narcotic substances.

5Capsules
CategoryNon-sterile pharmaceutical manufacturing
Description

Capsule manufacturing with powder and microgranule filling capabilities at Fontenay-sous-Bois and Osny sites, including hormonal and allergen workshops, with full control of capsule mass.

6Syrups
CategoryNon-sterile pharmaceutical manufacturing
Description

Syrup manufacturing and packaging in glass or plastic bottles (50-150 ml) at Hérouville-Saint-Clair site, with two syrup lines including a 5,000-l manufacturing tank and filling under nitrogen atmosphere.

7Creams, Ointments and Lotions
CategoryNon-sterile pharmaceutical manufacturing
Description

Topical preparations including creams and ointments filled into aluminum tubes (15-100 g) and lotions in plastic bottles (up to 250 ml) at Hérouville-Saint-Clair site.

8Drinkable Drops
CategoryNon-sterile pharmaceutical manufacturing
Description

Drinkable drops manufacturing at Hérouville-Saint-Clair in 30-ml vials with dropper pipette, including steroid hormones.

9Narcotics and Psychotropics Manufacturing
CategorySpecialty pharmaceutical manufacturing
Description

Manufacturing of drugs with psychoactive properties subject to strict regulation; Fontenay-sous-Bois site holds ANSM authorization for narcotics and psychotropics with full traceability.

10Highly Potent Compounds Manufacturing
CategorySpecialty pharmaceutical manufacturing
Description

Highly potent compounds including allergens, hormones, and oncological products (cytotoxic and cytostatic) manufactured at Braine-l'Alleud, Hérouville-Saint-Clair, and Osny sites, effective at very low doses.

11Biological Products Manufacturing
CategorySpecialty pharmaceutical manufacturing
Description

Biological drugs including monoclonal antibodies, ADC (antibody-drug conjugates), mRNA and DNA, peptides and proteins manufactured at Braine-l'Alleud and Hérouville-Saint-Clair sites with ANSM authorization for biological products.

12Cenexi Services (Pharmaceutical Development & Industrial Transfer)
CategoryPharmaceutical development services
Description

Comprehensive pharmaceutical development services including formulation, analytical development, pharmaceutical form development, industrial transfer, and regulatory support; 110 experts across three sites supporting projects from preformulation to commercial production.

13Regulatory Services
CategoryPharmaceutical development services
Description

Market authorization file creation (CTD Module 3), variation files, and regulatory strategy support across 124 country registrations including ANSM (France), AFMPS (Belgium), ANVISA (Brazil), FDA (USA), KFDA (Korea), PMDA (Japan).

14Stability Testing Services
CategoryPharmaceutical development services
Description

Pre-stability, regulatory, and commercial stability studies following ICH conditions: -20°C, 5°C, 25°C/60% RH, 30°C/65% RH, 30°C/75% RH, 40°C/75% RH, and photostability testing.

15Clinical Batch Manufacturing
CategoryPharmaceutical development services
Description

Drug product manufacturing for clinical trials including solid forms with hormones (1 kg minimum batches), sterile liquid forms including cytotoxic (1 L minimum), and lyophilized forms.

16ZENEO® Needle-free Auto-injector Fill-Finish
Scale indicator12 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
1Humanigen
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-02-09
Description

Cenexi signed a partnership with Humanigen (an American clinical-stage biopharmaceutical company) in February 2022 for the transfer of technology and manufacturing of lenzilumab, one of the most promising treatments for severe forms of COVID-19. Manufacturing takes place at Cenexi's Hérouville-Saint-Clair site. Cenexi may also handle regulatory services and potentially manage the entire supply chain for lenzilumab in France and Europe. Humanigen also submitted a request for early access to lenzilumab in France to the French National Authority for Health (HAS).

cenexi.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-01-18
Description

Cenexi manufactures ProvayBlue® (methylene blue) for Provepharm, a French pharmaceutical company. The FDA authorized Cenexi's Hérouville-Saint-Clair site to produce ProvayBlue® in vials for the US market in January 2022. Previously, Cenexi's Fontenay-sous-Bois site had been FDA-approved since 2016 for ProvayBlue® ampoules. Provepharm also obtained its own FDA approval for its active ingredient manufacturing unit. This partnership demonstrates Cenexi's ability to manufacture a customer's product portfolio across multiple Cenexi sites.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-06-30
Description

Cenexi entered an agreement with OSE Immunotherapeutics (a Nantes-based biotech) in June 2021 to manufacture clinical batches of CoVepiT, a next-generation multi-target COVID-19 vaccine candidate in Phase 1 clinical trial. Cenexi handles peptide processing, sterile emulsion production, and packaging of clinical batches at its Hérouville-Saint-Clair site with a filling capacity of 40 million bottles per year. The agreement covers Phase 1 clinical trial batches and potentially further clinical phases subject to positive results.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-05-01
Description

Cenexi and Crossject entered a strategic partnership in 2016 for the development, filling, and final assembly of ZENEO®, a needle-free auto-injector protected by over 400 patents. Cenexi developed novel industrial filling processes (patent filed) with custom equipment for this complex device at its Braine-l'Alleud site in Belgium. The partnership expanded in 2021 to include industrial-scale production ramp-up, with Cenexi handling filling of 8 molecules (Midazolam, Adrenaline, Naloxone, Terbutaline, Hydrocortisone, Methotrexate, Sumatriptan, and Apomorphine) primarily for emergency situations. Cenexi is positioned as Crossject's reference industrial partner for long-term commercial supply.

Strategic tierCoreTypeOthers
Description

Cenexi is a European subsidiary of Gland Pharma (an Indian pharmaceutical company listed on Indian stock exchanges). Gland Pharma acquired Cenexi and has been investing in its capacity expansion. The CDMO business, with Cenexi at its core, accounts for nearly half of Gland Pharma's consolidated revenue and grew 28% in FY26. Gland Pharma guided for 15% medium-term revenue growth and planned ₹2,000 crore capex over five years for CDMO expansion.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

French-headquartered CDMO with multi-site sterile and non-sterile manufacturing across Europe. Directly comparable to Cenexi in target customers (big pharma + biotech), pharmaceutical forms (sterile injectables, tablets, capsules), and European site footprint. Alain Kirchmeyer (Cenexi's CEO from Feb 2024) previously held senior roles at Delpharm, indicating direct competitive familiarity.

TypeDirect peer
Description

French CDMO specializing in sterile unit-dose pharmaceuticals (single-dose vials, Blow-Fill-Seal, pre-filled syringes) for ophthalmic, respiratory, and injectable applications. Closely comparable to Cenexi in sterile fill-finish focus and French CDMO positioning; Kirchmeyer also came from Unither.

3Recipharm
TypeDirect peer
Description

European CDMO with extensive sterile injectable manufacturing (lyophilized vials, PFS) and a similar focus on serving big-pharma and biotech customers. Comparable in scale, multi-site footprint, and sterile fill-finish specialization to Cenexi's Braine-l'Alleud and Hérouville-Saint-Clair sites.

4Fareva
TypeDirect peer
Description

French-headquartered CDMO with sterile injectable, biotech, and API manufacturing capabilities across Europe. Comparable to Cenexi in customer base (big pharma + generics), multi-site European operations, and service breadth spanning sterile and non-sterile forms.

TypeDirect peer
Description

German-headquartered European CDMO offering sterile liquids, lyophilized injectables, pre-filled syringes, and solid dosage forms. Directly comparable to Cenexi in sterile manufacturing specialization, pharmaceutical forms, and serving pharma/biotech customers in Europe.

TypeBroad incumbent
Description

Global CDMO with large-scale sterile fill-finish, biologics, and PFS capabilities. Overlaps with Cenexi in sterile injectable manufacturing and biologics CDMO but operates at much greater scale across multiple continents. Represents the broader competitive set rather than a like-for-like peer.

TypeBroad incumbent
Description

Swiss global CDMO leader with extensive sterile injectable, biologics (mAbs, ADC), and small-molecule API capabilities. Competes with Cenexi for biologics and complex injectable contracts but at substantially greater scale and with a more global footprint.

TypeBroad incumbent
Description

Indian-headquartered global CDMO with sterile injectable manufacturing, ADC capabilities, and high-potency API. Comparable to Cenexi in sterile injectables and HP-API focus; notably, Piramal is also a Cenexi customer, indicating its CDMO offering competes with some of the same customers Cenexi serves.

TypeOthers
Description

Indian-listed injectable manufacturer and parent company of Cenexi. Operates its own sterile injectable CDMO business (which accounts for nearly half of consolidated revenue), and is therefore both a parent and a partial peer — the integrated CDMO business overlaps with Cenexi's offerings.

TypeBroad incumbent
Description

Global pharma services division offering sterile fill-finish, biologics, and clinical manufacturing. Overlaps with Cenexi in commercial sterile manufacturing and biologics services but operates as part of a much larger diversified life sciences platform.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers16 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature7 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries2 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance7 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Cenexi

Pharmaceutical Contract Manufacturing (CDMO)cenexi.com

Cenexi is a French CDMO founded in 2004 that manufactures sterile injectable pharmaceuticals — ampoules, vials, pre-filled syringes, and lyophilized products — across four sites in France and Belgium, with specialization in high-potency, oncology, and biological products for ~100 pharmaceutical customers in 124 countries.

What Cenexi does

Cenexi is a French-headquartered Contract Development and Manufacturing Organization (CDMO) founded in 2004 that specializes in sterile injectable pharmaceutical manufacturing. The company operates four production sites — Fontenay-sous-Bois (headquarters), Osny, and H\u00e9rouville-Saint-Clair in France, plus Braine-l'Alleud in Belgium — with a combined workforce of approximately 1,500 people and ~€200M in revenue as of 2021. Cenexi's core capabilities include aseptic filling of ampoules (410 million units/year, the highest capacity in Europe), sterile liquid and freeze-dried vials (68 million/year), pre-filled syringes (37 million/year), and non-sterile forms (tablets, capsules, syrups, creams). The company maintains specialized expertise in high-potency compounds, oncology products, hormonal therapies, narcotics, and biologicals (monoclonal antibodies, ADCs, mRNA/DNA, peptides), supported by six freeze-dryers and dedicated cytotoxic handling infrastructure across multiple sites. Cenexi Services, with 110 dedicated experts, provides formulation, analytical development, industrial transfer, and regulatory support, enabling an end-to-end offering from early development through commercial manufacturing.

Cenexi operates as a B2B contract manufacturer, generating revenue through long-term manufacturing agreements and project-based development services. Its customer base spans large pharmaceutical companies (Sanofi, Piramal), specialty pharma (Advanz, Biocodex, Cheplapharm, Debiopharm, Nordic Pharma, Provepharm, Urogen), generics manufacturers (Arrow, Mithra), and innovative biotechs (Crossject, OSE Immunotherapeutics, Humanigen). The company is registered with health authorities in 124 countries and holds FDA, ANSM, AFMPS, ANVISA, KFDA, and PMDA approvals, enabling global market access for customers. A filed patent for a novel industrial filling process for the Crossject ZENEO® needle-free auto-injector illustrates Cenexi's capability in drug-device combination manufacturing. Cenexi is a wholly-owned subsidiary of Gland Pharma, an Indian pharmaceutical company; Gland Pharma's CDMO segment (anchored by Cenexi) grew 28% in FY26, and Cenexi is expected to deliver low double-digit growth in FY27 with stronger momentum in FY28 as a €100M+ modernization program and new capacity come online. The strategic mix is shifting toward sterile (targeting 80% of revenue by 2026/2027, up from 70% in 2022), with growth driven by biologics manufacturing authorization, new product lines, and long-term commercial supply agreements.

Cenexi firmographics

Firmographics
Name
Cenexi
Legal name
Cenexi S.A.S.
Website
https://cenexi.com
Company type
Private
Founded year
2004
Operating status
Operating
Headcount range
501–1,000 employees
Short description
Cenexi is a French CDMO founded in 2004 that manufactures sterile injectable pharmaceuticals — ampoules, vials, pre-filled syringes, and lyophilized products — across four sites in France and Belgium, with specialization in high-potency, oncology, and biological products for ~100 pharmaceutical customers in 124 countries.
Ownership category
akta.pro rank

Cenexi industry classification

Industry
Product category
Pharmaceutical Contract Manufacturing (CDMO)
NAICS
Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAGABAH
Sterile Fill-Finish & Aseptic Manufacturing CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAC
Biologics (mAbs/Recombinant Proteins) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAG
Drug Substance–Drug Product Integrated CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAK
Clinical Trial Material (CTM) Manufacturing & Supply CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)

Keywords

  • Sterile pharmaceutical manufacturing
  • Contract pharmaceutical development
  • Sterile injectable fill-finish
  • Lyophilized drug manufacturing
  • Pharmaceutical CDMO services

Where Cenexi is headquartered

Location

Headquarters

HQ city
Fontenay-sous-bois
HQ country
France
HQ region
Europe

Offices4 records

Markets served

Cenexi business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Infrastructure, Technology or R&D, Supply Chain, Marketing or Sales

Revenue model

  1. CDMO Manufacturing Contracts: Cenexi operates as a Contract Development and Manufacturing Organization (CDMO), generating revenue through long-term manufacturing contracts with pharmaceutical companies, biotechs, and generic manufacturers. Revenue is generated through contractual manufacturing agreements for sterile and non-sterile pharmaceutical forms, with recurring revenue from commercial batches and development fees from new product transfers.
  2. Pharmaceutical Development Services: Cenexi generates revenue from formulation activities, analytical and pharmaceutical form developments, industrial transfer, and regulatory support services through its Cenexi Services entity (110 experts). Services are provided upstream (during drug development) and downstream (regulatory and logistical support), billed as project-based or milestone-based professional services.
  3. Parent Company (Gland Pharma) CDMO Integration: Cenexi, as a European subsidiary of Gland Pharma, contributes to the parent's CDMO business which accounts for nearly half of Gland Pharma's consolidated revenue and grew 28% in FY26. Cenexi is expected to deliver low double-digit revenue growth in FY27 and stronger momentum in FY28 on the back of capacity additions and new product lines.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels5 records

Cenexi product offering

Product offering

Core offering

Cenexi is a French Contract Development and Manufacturing Organization (CDMO) that produces sterile and non-sterile pharmaceutical forms on behalf of pharmaceutical laboratories, innovative biotechs, and generic manufacturers. Its core manufacturing covers injectable ampoules (highest capacity in Europe at 410 million units/year), sterile liquid and freeze-dried vials, and pre-filled syringes, supported by specialized handling of highly potent compounds, cytotoxics, hormones, narcotics, and biological products (mAbs, ADCs, mRNA/DNA, peptides). It complements manufacturing with pharmaceutical development, industrial transfer, regulatory support, and stability testing services.

Product overview

Cenexi is a French Contract Development and Manufacturing Organization (CDMO) founded in 2004, operating as a single integrated offering with four production sites (Fontenay-sous-Bois, Osny, and Hérouville-Saint-Clair in France; Braine-l'Alleud in Belgium). The company provides an end-to-end service spanning pharmaceutical development (via Cenexi Services with 110 experts), regulatory support, manufacturing, and packaging. The core products include sterile forms (ampoules, vials, pre-filled syringes) representing approximately 70% of business, and non-sterile forms (tablets, capsules, syrups, creams, lotions, drops). Special capabilities cover narcotics/psychotropics, highly potent compounds (allergens, hormones, oncology), and biological products (monoclonal antibodies, ADC, mRNA/DNA, peptides). The company serves innovative biotechs as a preferred partner while also manufacturing commercial batches for generic and originator pharma companies, with registrations in 124 countries worldwide.

Differentiator

Problem solved

Functional benefit

Products and services

  • Injectable Ampoules Aseptic filling of injectable ampoules (1-25 ml) with the highest production capacity in Europe at 410 million units per year across 8 filling lines (6 at Fontenay-sous-Bois, 2 at Hérouville-Saint-Clair); three lines are Annex 1-compliant.
  • Sterile Vials (Liquid and Freeze-dried) Sterile liquid and freeze-dried vials (2-100 ml) with combined capacity of 68 million units per year across two filling lines at Braine-l'Alleud and Hérouville-Saint-Clair; six freeze dryers with 110 m² useful area, Annex 1-compliant.
  • Pre-filled Syringes Sterile pre-filled syringes (1-50 ml) manufactured at Hérouville-Saint-Clair and Braine-l'Alleud with combined capacity of 37 million units per year, supporting conventional, highly potent, and biological substances including mRNA, DNA, peptides/proteins, monoclonal antibodies, and ADC.
  • Tablets Non-sterile tablet manufacturing with capacity of 1 billion tablets per year including hormonal tablets; capabilities in direct compression, wet/alcohol granulation, double compression, and coating at Fontenay-sous-Bois and Osny sites; handles conventional and narcotic substances.
  • Capsules Capsule manufacturing with powder and microgranule filling capabilities at Fontenay-sous-Bois and Osny sites, including hormonal and allergen workshops, with full control of capsule mass.
  • Syrups Syrup manufacturing and packaging in glass or plastic bottles (50-150 ml) at Hérouville-Saint-Clair site, with two syrup lines including a 5,000-l manufacturing tank and filling under nitrogen atmosphere.
  • Creams, Ointments and Lotions Topical preparations including creams and ointments filled into aluminum tubes (15-100 g) and lotions in plastic bottles (up to 250 ml) at Hérouville-Saint-Clair site.
  • Drinkable Drops Drinkable drops manufacturing at Hérouville-Saint-Clair in 30-ml vials with dropper pipette, including steroid hormones.
  • Narcotics and Psychotropics Manufacturing Manufacturing of drugs with psychoactive properties subject to strict regulation; Fontenay-sous-Bois site holds ANSM authorization for narcotics and psychotropics with full traceability.
  • Highly Potent Compounds Manufacturing Highly potent compounds including allergens, hormones, and oncological products (cytotoxic and cytostatic) manufactured at Braine-l'Alleud, Hérouville-Saint-Clair, and Osny sites, effective at very low doses.
  • Biological Products Manufacturing Biological drugs including monoclonal antibodies, ADC (antibody-drug conjugates), mRNA and DNA, peptides and proteins manufactured at Braine-l'Alleud and Hérouville-Saint-Clair sites with ANSM authorization for biological products.
  • Cenexi Services (Pharmaceutical Development & Industrial Transfer) Comprehensive pharmaceutical development services including formulation, analytical development, pharmaceutical form development, industrial transfer, and regulatory support; 110 experts across three sites supporting projects from preformulation to commercial production.
  • Regulatory Services Market authorization file creation (CTD Module 3), variation files, and regulatory strategy support across 124 country registrations including ANSM (France), AFMPS (Belgium), ANVISA (Brazil), FDA (USA), KFDA (Korea), PMDA (Japan).
  • Stability Testing Services Pre-stability, regulatory, and commercial stability studies following ICH conditions: -20°C, 5°C, 25°C/60% RH, 30°C/65% RH, 30°C/75% RH, 40°C/75% RH, and photostability testing.
  • Clinical Batch Manufacturing Drug product manufacturing for clinical trials including solid forms with hormones (1 kg minimum batches), sterile liquid forms including cytotoxic (1 L minimum), and lyophilized forms.
  • ZENEO® Needle-free Auto-injector Fill-Finish

Quantifiable outcome

  • 410 million ampoules produced annually — highest capacity in Europe
  • +7 more outcomes

Companies that use Cenexi

Customer profile

Named customers16 records

Segments4 records

Ideal customer profiles3 records

Cenexi technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature7 records

Cenexi partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered core.

  • HumanigencoreStrategic or Co-development Partner · 9 February 2022Cenexi signed a partnership with Humanigen (an American clinical-stage biopharmaceutical company) in February 2022 for the transfer of technology and manufacturing of lenzilumab, one of the most promising treatments for severe forms of COVID-19. Manufacturing takes place at Cenexi's Hérouville-Saint-Clair site. Cenexi may also handle regulatory services and potentially manage the entire supply chain for lenzilumab in France and Europe. Humanigen also submitted a request for early access to lenzilumab in France to the French National Authority for Health (HAS).
  • ProvepharmcoreStrategic or Co-development Partner · 18 January 2022Cenexi manufactures ProvayBlue® (methylene blue) for Provepharm, a French pharmaceutical company. The FDA authorized Cenexi's Hérouville-Saint-Clair site to produce ProvayBlue® in vials for the US market in January 2022. Previously, Cenexi's Fontenay-sous-Bois site had been FDA-approved since 2016 for ProvayBlue® ampoules. Provepharm also obtained its own FDA approval for its active ingredient manufacturing unit. This partnership demonstrates Cenexi's ability to manufacture a customer's product portfolio across multiple Cenexi sites.
  • OSE ImmunotherapeuticscoreStrategic or Co-development Partner · 30 June 2021Cenexi entered an agreement with OSE Immunotherapeutics (a Nantes-based biotech) in June 2021 to manufacture clinical batches of CoVepiT, a next-generation multi-target COVID-19 vaccine candidate in Phase 1 clinical trial. Cenexi handles peptide processing, sterile emulsion production, and packaging of clinical batches at its Hérouville-Saint-Clair site with a filling capacity of 40 million bottles per year. The agreement covers Phase 1 clinical trial batches and potentially further clinical phases subject to positive results.
  • CrossjectcoreStrategic or Co-development Partner · 1 May 2021Cenexi and Crossject entered a strategic partnership in 2016 for the development, filling, and final assembly of ZENEO®, a needle-free auto-injector protected by over 400 patents. Cenexi developed novel industrial filling processes (patent filed) with custom equipment for this complex device at its Braine-l'Alleud site in Belgium. The partnership expanded in 2021 to include industrial-scale production ramp-up, with Cenexi handling filling of 8 molecules (Midazolam, Adrenaline, Naloxone, Terbutaline, Hydrocortisone, Methotrexate, Sumatriptan, and Apomorphine) primarily for emergency situations. Cenexi is positioned as Crossject's reference industrial partner for long-term commercial supply.
  • Gland Pharma (Parent Company)coreOthersCenexi is a European subsidiary of Gland Pharma (an Indian pharmaceutical company listed on Indian stock exchanges). Gland Pharma acquired Cenexi and has been investing in its capacity expansion. The CDMO business, with Cenexi at its core, accounts for nearly half of Gland Pharma's consolidated revenue and grew 28% in FY26. Gland Pharma guided for 15% medium-term revenue growth and planned ₹2,000 crore capex over five years for CDMO expansion.

Scale indicators12 records

Recent moves7 records

Expansion highlights6 records

Cenexi competitors and assessment

Company assessment

Direct peers

  • Delpharm: French-headquartered CDMO with multi-site sterile and non-sterile manufacturing across Europe. Directly comparable to Cenexi in target customers (big pharma + biotech), pharmaceutical forms (sterile injectables, tablets, capsules), and European site footprint. Alain Kirchmeyer (Cenexi's CEO from Feb 2024) previously held senior roles at Delpharm, indicating direct competitive familiarity.
  • Unither Pharmaceuticals: French CDMO specializing in sterile unit-dose pharmaceuticals (single-dose vials, Blow-Fill-Seal, pre-filled syringes) for ophthalmic, respiratory, and injectable applications. Closely comparable to Cenexi in sterile fill-finish focus and French CDMO positioning; Kirchmeyer also came from Unither.
  • Recipharm: European CDMO with extensive sterile injectable manufacturing (lyophilized vials, PFS) and a similar focus on serving big-pharma and biotech customers. Comparable in scale, multi-site footprint, and sterile fill-finish specialization to Cenexi's Braine-l'Alleud and Hérouville-Saint-Clair sites.
  • Fareva: French-headquartered CDMO with sterile injectable, biotech, and API manufacturing capabilities across Europe. Comparable to Cenexi in customer base (big pharma + generics), multi-site European operations, and service breadth spanning sterile and non-sterile forms.
  • Aenova: German-headquartered European CDMO offering sterile liquids, lyophilized injectables, pre-filled syringes, and solid dosage forms. Directly comparable to Cenexi in sterile manufacturing specialization, pharmaceutical forms, and serving pharma/biotech customers in Europe.

Broad incumbents

  • Catalent: Global CDMO with large-scale sterile fill-finish, biologics, and PFS capabilities. Overlaps with Cenexi in sterile injectable manufacturing and biologics CDMO but operates at much greater scale across multiple continents. Represents the broader competitive set rather than a like-for-like peer.
  • Lonza Group: Swiss global CDMO leader with extensive sterile injectable, biologics (mAbs, ADC), and small-molecule API capabilities. Competes with Cenexi for biologics and complex injectable contracts but at substantially greater scale and with a more global footprint.
  • Piramal Pharma Solutions: Indian-headquartered global CDMO with sterile injectable manufacturing, ADC capabilities, and high-potency API. Comparable to Cenexi in sterile injectables and HP-API focus; notably, Piramal is also a Cenexi customer, indicating its CDMO offering competes with some of the same customers Cenexi serves.
  • Thermo Fisher Scientific (CDMO Services): Global pharma services division offering sterile fill-finish, biologics, and clinical manufacturing. Overlaps with Cenexi in commercial sterile manufacturing and biologics services but operates as part of a much larger diversified life sciences platform.

Others

  • Gland Pharma: Indian-listed injectable manufacturer and parent company of Cenexi. Operates its own sterile injectable CDMO business (which accounts for nearly half of consolidated revenue), and is therefore both a parent and a partial peer — the integrated CDMO business overlaps with Cenexi's offerings.

Market position

Strengths5 records

Weaknesses4 records

Competitive moat6 records

Key risks5 records

Key highlights7 records

Customer concentration

Cenexi social profiles

Digital presence

Cenexi compliance and trust

Trust signal

Compliance7 records

Cenexi financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Cenexi leadership team

Management profile

Number of profiles

Profiles2 records

Cenexi subsidiaries and ownership

Company hierarchy

Subsidiaries2 records

Cenexi funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Cenexi M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Cenexi

What does Cenexi do?

Cenexi is a French Contract Development and Manufacturing Organization (CDMO) that produces sterile and non-sterile pharmaceutical forms on behalf of pharmaceutical laboratories, innovative biotechs, and generic manufacturers. Its core manufacturing covers injectable ampoules (highest capacity in Europe at 410 million units/year), sterile liquid and freeze-dried vials, and pre-filled syringes, supported by specialized handling of highly potent compounds, cytotoxics, hormones, narcotics, and biological products (mAbs, ADCs, mRNA/DNA, peptides). It complements manufacturing with pharmaceutical development, industrial transfer, regulatory support, and stability testing services.

Is Cenexi a public or private company?

Cenexi is a private company. It is classified as corporate owned and is currently operating.

When was Cenexi founded?

Cenexi was founded in 2004. It employs 501 to 1,000 people.

Where is Cenexi based?

Cenexi is headquartered in Fontenay-sous-bois, France, in the Europe region.

How does Cenexi make money?

Three revenue lines are on record. CDMO Manufacturing Contracts are the primary driver. The others are pharmaceutical Development Services and parent Company (Gland Pharma) CDMO Integration.

Who are Cenexi's main competitors?

Direct peers on record are Delpharm, Unither Pharmaceuticals, Recipharm, Fareva and Aenova. Broad incumbents are Catalent, Lonza Group, Piramal Pharma Solutions and Thermo Fisher Scientific (CDMO Services). Gland Pharma is listed as an others.

Does Cenexi have an API?

No public API is recorded for Cenexi.

What industry is Cenexi in?

Cenexi's product category is Pharmaceutical Contract Manufacturing (CDMO). Its primary akta.pro industry code is HLAGABAH, Sterile Fill-Finish & Aseptic Manufacturing CDMO, with a secondary code of HLAGABAC, Biologics (mAbs/Recombinant Proteins) CDMO. Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
ScanXGland Pharma FY26 Results: Net profit surges 47% to ₹10,273 mnGland Pharma reported FY26 net profit of ₹10,273 million, up 47% year-on-year, with revenue of ₹64,307 million rising 14%. EBITDA grew 28% to ₹16,295 million, and the European subsidiary Cenexi narrowed losses significantly as revenues grew 25%.The Times of Indiagland pharma: Cenexi recovery, new product launches and capacity additions power Gland Pharma outlook - The Economic TimesGland Pharma stock surged to a 52-week high after the company reported strong March quarter and full-year performance, with the stock gaining 19% in three trading sessions. Its European subsidiary Cenexi has shown gradual profitability improvement and is expected to deliver low double-digit revenue growth in FY27 and stronger momentum in FY28 on the back of capacity additions and new product lines. The company guided for 15% medium-term revenue growth, with a ₹2,000 crore capital expenditure planned over five years to expand its CDMO business, which accounts for nearly half of consolidated revenue and grew 28% in FY26.The Times of Indiagland pharma: Gland Pharma shares in focus after subsidiary Cenexi gets 11 observations from French regulator - The Economic TimesGland Pharma's subsidiary Cenexi received 11 observations from France's drug regulator ANSM following a GMP inspection at its Fontenay manufacturing facility conducted between December 9-19, 2024. Cenexi has submitted a Corrective and Preventive Action (CAPA) plan, which has been accepted by the regulator, with measures to be implemented over a 3- to 12-month period. The company clarified that the observations will not impact manufacturing operations at the Fontenay site and remains committed to resolving the issues in coordination with the French regulator.The Times of IndiaGland Pharma Q4 Results: Net profit down 3% at Rs 186 crore - The Economic TimesGland Pharma Ltd reported a 3% decline in consolidated net profit to Rs 186.54 crore for Q4 FY25 ended March 31, 2025, compared to Rs 192.42 crore in the same period last year. Consolidated revenue from operations fell to Rs 1,424.91 crore from Rs 1,537.45 crore year-on-year, driven by a 10% decline in the US market to Rs 791.8 crore, though Europe saw 4% growth to Rs 280.2 crore. For full year FY25, consolidated net profit dropped 10% to Rs 698.53 crore as the company focuses on strategic realignment including biologics CDMO expansion and Cenexi turnaround.The Times of IndiaGland Pharma to fully acquire Europe-based Cenexi, Health News, ET HealthWorldGland Pharma entered into a put option agreement to fully acquire Europe-based CDMO Cenexi Group for up to EUR 120 million (about Rs 1,015 crore). Cenexi, founded in 2004, operates four manufacturing sites in France and Belgium and reported EUR 184.1 million revenue in 2021.The Times of IndiaCenexi Group: Gland Pharma acquires French CDMO Cenexi for €120 million - The Economic TimesGland Pharma has entered into an agreement to acquire 100% of French CDMO Cenexi Group for an equity value not exceeding €120 million. The acquisition provides Gland Pharma with a foothold in the European market, granting access to four manufacturing sites in France and Belgium along with specialized sterile fill-finish capabilities. This strategic move is intended to deepen Gland's presence in Europe and expand its global customer base through synergistic commercial benefits.Business StandardGland Pharma to acquire French firm Cenexi Group for Rs 1,000 croreGland Pharma has entered into a put option agreement to acquire the French firm Cenexi Group for an equity value not exceeding 20 million euros, approximately Rs 1,000 crore. The transaction is intended to expand Gland Pharma's contract development and manufacturing business in Europe and will be funded entirely through internal accruals.MintGland Pharma to buy Europe-based Cenexi for over ₹1,000 crore | Company Business NewsGland Pharma Ltd has agreed to acquire the French pharmaceutical firm Cenexi for 120 million euros (approximately ₹1,015 crore) through its Singapore-based subsidiary. The acquisition marks Gland Pharma's first international purchase and aims to expand its sterile injectable manufacturing capabilities within the European market.BenzingaHumanigen, Cenexi Ink Manufacture Pact For COVID-19 Candidate, Lenzilumab, In FranceHumanigen Inc. has selected Cenexi, a French CDMO, as a preferred supplier for its COVID-19 drug candidate lenzilumab in France and the European Union. The companies signed a five-year Master Supply Agreement for aseptic fill and finish services at Cenexi's Normandy site, with Humanigen planning to include the facility in future regulatory filings for COVID-19 and other indications. The collaboration also includes efforts to secure potential funding and capital equipment investment from AD Normandie and the Government of France, as well as pursuing an advanced purchase agreement for lenzilumab in France.